Puma Biotechnology Inc. (NYSE:PBYI)‘s stock had its “outperform” rating reiterated by equities research analysts at Credit Suisse Group AG in a research note issued to investors on Tuesday. They currently have a $111.00 price objective on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective would suggest a potential upside of 165.55% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Puma Biotechnology from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a report on Friday, August 12th. JPMorgan Chase & Co. set a $89.00 price objective on Puma Biotechnology and gave the company a “buy” rating in a report on Monday. RBC Capital Markets restated a “sector perform” rating and set a $46.00 price objective (up previously from $36.00) on shares of Puma Biotechnology in a report on Sunday, July 24th. Stifel Nicolaus upgraded Puma Biotechnology from a “hold” rating to a “buy” rating and boosted their price objective for the company from $61.00 to $88.00 in a report on Wednesday, September 21st. Finally, Vetr cut Puma Biotechnology from a “strong-buy” rating to a “strong sell” rating and set a $39.50 price objective for the company. in a report on Wednesday, August 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $68.56.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Shares of Puma Biotechnology (NYSE:PBYI) opened at 41.80 on Tuesday. Puma Biotechnology has a 1-year low of $19.74 and a 1-year high of $82.81. The stock’s market capitalization is $1.54 billion. The stock has a 50 day moving average price of $49.34 and a 200-day moving average price of $43.92.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas raised its position in Puma Biotechnology by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 465 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Puma Biotechnology by 112.0% in the third quarter. BNP Paribas Arbitrage SA now owns 2,133 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 1,127 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 1,740 shares during the last quarter. Quantbot Technologies LP bought a new position in Puma Biotechnology during the second quarter valued at approximately $183,000. Finally, Legal & General Group Plc raised its position in Puma Biotechnology by 142.4% in the second quarter. Legal & General Group Plc now owns 6,142 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 3,608 shares during the last quarter. 87.54% of the stock is owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

5 Day Chart for NYSE:PBYI

Receive News & Stock Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related stocks with our FREE daily email newsletter.